Our in vitro effects counsel that EAM-2201 should be examined in terms of possible in vivo pharmacokinetic drug–drug interactions attributable to time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 pursuits and competitive inhibition of UGT1A3 activity. This is the preview of membership information, log in by means of an institution https://campbelln383ujz5.sharebyblog.com/profile